Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

US immigration order strikes against biotech.

Levin JM, Holtzman SH, Maraganore J, Hastings PJ, Cohen R, Dahiyat B, Adams J, Adams C, Ahrens B, Albers J, Aspinall MG, Audia JE, Babler M, Barrett P, Barry Z, Bermingham N, Bloch S, Blum RI, Bolno PB, Bonney MW, Booth B, Bradbury DM, Brauer SK, Byers B, Cagnoni PJ, Cali BM, Ciechanover I, Clark C, Clayman MD, Cleland JL, Cobb P, Cooper R, Currie MG, Diekman J, Dobmeier EL, Doerfler D, Donley EL, Dunsire D, During M, Eckstein JW, Elenko E, Exter NA, Fleming JJ, Flesher GJ, Formela JF, Forrester R, Francois C, Franklin H, Freeman MW, Furst H, Gage LP, Galakatos N, Gallagher BM, Geraghty JA, Gill S, Goeddel DV, Goldsmith MA, Gowen M, Goyal V, Graney T, Grayzel D, Greene B, Grint P, Gutierrez-Ramos JC, Haney B, Ha-Ngoc T, Harris T, Hasnain F, Hata YS, Hecht P, Henshaw L, Heyman R, Hoppenot H, Horvitz HR, Hughes TE, Hutton WS, Isaacs ST, Jenkins A, Jonker J, Kaplan J, Karsen P, Keiper J, Kim J, Kindler J, King R, King V, Kjellson N, Koenig S, Koenig G, Kolchinsky P, Laikind P, Langer RB, Lee JJ, Leff JS, Leicher BA, Leschly N, Levin A, Levin M, Levine AJ, Levy A, Liu DR, Lodish HF, Lopatin U, Love TW, Macdonald G, Maderis GJ, Mahadevia A, Mahanthappa NK, Martin JF, Martin A, Martucci WE, McArthur JG, McCann CM, McCarthy SA, McDonough CG, Mendlein J, Miller L, Miralles D, Moch KI, More B, Myers AG, Narachi MA, Nashat A, Nelson W, Newell WJ, Olle B, Osborn JE, Owens JC, Pande A, Papadopoulos S, Parker HS, Parmar KM, Patterson MR, Paul SM, Perez R, Perry M, Pfeffer CG, Powell M, Pruzanski M, Purcell DJ, Rakhit A, Ramamoorthi K, Rastetter W, Rawcliffe AA, Reid LE, Renaud RC, Rhodes JP, Rieflin WJ, Robins C, Rocklage SM, Rosenblatt M, Rosin JG, Rutter WJ, Saha S, Samuels C, Sato VL, Scangos G, Scarlett JA, Schenkein D, Schreiber SL, Schwab A, Sekhri P, Shah R, Shenk T, Siegall CB, Simon NJ, Simonian N, Stein J, Su M, Szela MT, Taglietti M, Tandon N, Termeer H, Thornberry NA, Tolar M, Ulevitch R, Vaishnaw AK, VanLent A, Varsavsky M, Vlasuk GP, Vounatsos M, Waksal SG, Warma N, Watts RJ, Werber Y, Westphal C, Wierenga W, Williams DE, Williams LR, Xanthopoulos KG, Zohar D, Zweifach SS.

Nat Biotechnol. 2017 Mar 7;35(3):204-206. doi: 10.1038/nbt.3824. No abstract available.

PMID:
28267733
2.
3.

Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition.

Buck E, Eyzaguirre A, Barr S, Thompson S, Sennello R, Young D, Iwata KK, Gibson NW, Cagnoni P, Haley JD.

Mol Cancer Ther. 2007 Feb;6(2):532-41.

5.

Effects of smoking on the pharmacokinetics of erlotinib.

Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, Cagnoni PJ.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2166-71.

6.

Whole-brain radiotherapy with or without efaproxiral for the treatment of brain metastases: Determinants of response and its prognostic value for subsequent survival.

Stea B, Suh JH, Boyd AP, Cagnoni PJ, Shaw E; REACH Study Group.

Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1023-30. Epub 2006 Jan 30.

PMID:
16446056
7.

Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases.

Suh JH, Stea B, Nabid A, Kresl JJ, Fortin A, Mercier JP, Senzer N, Chang EL, Boyd AP, Cagnoni PJ, Shaw E.

J Clin Oncol. 2006 Jan 1;24(1):106-14. Epub 2005 Nov 28.

PMID:
16314619
8.

Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer.

Choy H, Nabid A, Stea B, Scott C, Roa W, Kleinberg L, Ayoub J, Smith C, Souhami L, Hamburg S, Spanos W, Kreisman H, Boyd AP, Cagnoni PJ, Curran WJ.

J Clin Oncol. 2005 Sep 1;23(25):5918-28.

PMID:
16135463
9.

Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies.

Nieto Y, Shpall EJ, Bearman SI, McSweeney PA, Cagnoni PJ, Matthes S, Gustafson D, Long M, Barón AE, Jones RB.

Biol Blood Marrow Transplant. 2005 Apr;11(4):297-306.

11.

Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients.

Miller CB, Waller EK, Klingemann HG, Dignani MC, Anaissie EJ, Cagnoni PJ, McSweeney P, Fleck PR, Fruchtman SM, McGuirk J, Chao NJ.

Bone Marrow Transplant. 2004 Mar;33(5):543-8.

PMID:
14730342
12.

Invasive mycotic infections caused by Chaetomium perlucidum, a new agent of cerebral phaeohyphomycosis.

Barron MA, Sutton DA, Veve R, Guarro J, Rinaldi M, Thompson E, Cagnoni PJ, Moultney K, Madinger NE.

J Clin Microbiol. 2003 Nov;41(11):5302-7. Review.

13.

Nonmyeloablative allogeneic hematopoietic stem cell transplantation for congenital sideroblastic anemia.

Medeiros BC, Kolhouse JF, Cagnoni PJ, Ryder J, Nieto Y, Rabinovitch R, Shpall EJ, Bearman SI, Jones RB, McSweeney PA.

Bone Marrow Transplant. 2003 Jun;31(11):1053-5.

PMID:
12774059
14.

Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.

Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W, Blume K, Niland J, Palmer JM, Vaughan W, Fernandez H, Champlin R, Forman S, Andersson BS.

Biol Blood Marrow Transplant. 2002;8(9):493-500.

15.

Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study.

Andersson BS, Kashyap A, Gian V, Wingard JR, Fernandez H, Cagnoni PJ, Jones RB, Tarantolo S, Hu WW, Blume KG, Forman SJ, Champlin RE.

Biol Blood Marrow Transplant. 2002;8(3):145-54.

16.

Biokinetics of yttrium-90--labeled huBrE-3 monoclonal antibody.

Johnson TK, Cole W, Quaife RA, Lear JL, Ceriani RL, Jones RB, Cagnoni PJ.

Cancer. 2002 Feb 15;94(4 Suppl):1240-8.

17.

Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer.

Nieto Y, Nawaz S, Jones RB, Shpall EJ, Cagnoni PJ, McSweeney PA, Barón A, Razook C, Matthes S, Bearman SI.

J Clin Oncol. 2002 Feb 1;20(3):707-18.

PMID:
11821452
18.
19.

Intensive chemotherapy for progressive chronic lymphocytic leukemia administered early after a nonmyeloablative allograft.

Nieto Y, Bearman SI, Shpall EJ, Jones RB, Cagnoni PJ, Rabinovitch RA, McSweeney PA.

Bone Marrow Transplant. 2001 Dec;28(11):1083-6.

20.

Topical transforming growth factor-beta3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors.

Foncuberta MC, Cagnoni PJ, Brandts CH, Mandanas R, Fields K, Derigs HG, Reed E, Sonis ST, Fay J, LeVeque F, Pouillart P, Schrezenmeier H, Emmons R, Thiel E; Investigators in TGF-beta3/OM Study Protocols 203/205.

J Immunother. 2001 Jul-Aug;24(4):384-8.

PMID:
11565840
21.

Status of high-dose chemotherapy for breast cancer: a review.

Nieto Y, Champlin RE, Wingard JR, Vredenburgh JF, Elias AD, Richardson P, Glaspy J, Jones RB, Stiff PJ, Bearman SI, Cagnoni PJ, McSweeney PA, LeMaistre CF, Pecora AL, Shpall EF.

Biol Blood Marrow Transplant. 2000;6(5):476-95. Review.

22.

Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer.

McNiece I, Jones R, Bearman SI, Cagnoni P, Nieto Y, Franklin W, Ryder J, Steele A, Stoltz J, Russell P, McDermitt J, Hogan C, Murphy J, Shpall EJ.

Blood. 2000 Nov 1;96(9):3001-7.

23.

Peripheral blood stem cell transplantation in breast cancer.

Shpall EJ, Jones RB, Bearman SI, Cagnoni PJ, Nieto Y, McNiece IK.

Baillieres Best Pract Res Clin Haematol. 1999 Mar-Jun;12(1-2):219-32. Review.

PMID:
11000995
24.

Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation.

Nieto Y, Russ P, Everson G, Bearman SI, Cagnoni PJ, Jones RB, Shpall EJ.

Bone Marrow Transplant. 2000 Jul;26(1):109-11.

25.

Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients.

Cagnoni PJ, Walsh TJ, Prendergast MM, Bodensteiner D, Hiemenz S, Greenberg RN, Arndt CA, Schuster M, Seibel N, Yeldandi V, Tong KB.

J Clin Oncol. 2000 Jun;18(12):2476-83. Erratum in: J Clin Oncol 2000 Aug;18(16):3064.

PMID:
10856108
26.

Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer.

Nieto Y, Cagnoni PJ, Bearman SI, Shpall EJ, Matthes S, Jones RB.

Biol Blood Marrow Transplant. 2000;6(2A):198-203.

PMID:
10816028
27.

Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation.

Nieto Y, Cagnoni PJ, Nawaz S, Shpall EJ, Yerushalmi R, Cook B, Russell P, McDermit J, Murphy J, Bearman SI, Jones RB.

J Clin Oncol. 2000 May;18(10):2070-80.

PMID:
10811672
28.

Philadelphia chromosome-negative engraftment after autologous transplantation with granulocyte-macrophage colony-stimulating factor for chronic myeloid leukemia.

Gladstone DE, Bedi A, Miller CB, Noga SJ, Griffin CA, Piantadosi S, Cagnoni PJ, Brodsky RA, Smith BD, Douglas TT, Shpall EJ, Jones RJ.

Biol Blood Marrow Transplant. 1999;5(6):394-9.

29.

A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant.

Nieto Y, Cagnoni PJ, Shpall EJ, Xu X, Murphy J, Vredenburgh J, Chao NJ, Bearman SI, Jones RB.

Clin Cancer Res. 1999 Nov;5(11):3425-31.

30.

Optic disc and retinal microvasculopathy after high-dose chemotherapy and autologous hematopoietic progenitor cell support.

Johnson DW, Cagnoni PJ, Schossau TM, Stemmer SM, Grayeb DE, Baron AE, Shpall EJ, Bearman SI, McDermitt J, Jones RB.

Bone Marrow Transplant. 1999 Oct;24(7):785-92.

31.

High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy.

Bearman S, Vredenburgh J, Cagnoni P, Shpall E, Nieto Y, Ross M, Peters W, Jones R.

Bone Marrow Transplant. 1999 Sep;24(5):491-5.

32.

Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics.

Cagnoni PJ, Matthes S, Day TC, Bearman SI, Shpall EJ, Jones RB.

Bone Marrow Transplant. 1999 Jul;24(1):1-4.

33.

Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease.

Nieto Y, Cagnoni PJ, Shpall EJ, Matthes S, Barón A, Jones RB, Bearman SI.

Clin Cancer Res. 1999 Jul;5(7):1731-7.

34.

Post-mortem incidental finding of cytomegalovirus oophoritis after an allogeneic stem cell transplant.

Nieto Y, Ross M, Gianani R, Shpall EJ, Cagnoni PJ, Bearman SI, Jones RB.

Bone Marrow Transplant. 1999 Jun;23(12):1323-4.

35.

Ex-vivo expansion of hematopoietic progenitor cells: preliminary results in breast cancer.

McNiece I, Jones R, Cagnoni P, Bearman S, Nieto Y, Shpall EJ.

Hematol Cell Ther. 1999 Apr;41(2):82-6.

PMID:
10344558
36.

Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea.

Nieto Y, Xu X, Cagnoni PJ, Matthes S, Shpall EJ, Bearman SI, Murphy J, Jones RB.

Clin Cancer Res. 1999 Apr;5(4):747-51.

37.

Acute encephalopathy: a new toxicity associated with high-dose paclitaxel.

Nieto Y, Cagnoni PJ, Bearman SI, Shpall EJ, Matthes S, DeBoom T, Barón A, Jones RB.

Clin Cancer Res. 1999 Mar;5(3):501-6.

38.

High-dose chemotherapy in gynecologic malignancies.

Nieto Y, Cagnoni PJ, Shpall EJ.

Cancer Treat Res. 1998;95:277-85. Review. No abstract available.

PMID:
9619289
39.

High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer.

Cagnoni PJ, Nieto Y, Shpall EJ, Bearman SI, Barón AE, Ross M, Matthes S, Dunbar SE, Jones RB.

J Clin Oncol. 1998 May;16(5):1661-8.

PMID:
9586876
40.

White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy.

Brown MS, Stemmer SM, Simon JH, Stears JC, Jones RB, Cagnoni PJ, Sheeder JL.

AJNR Am J Neuroradiol. 1998 Feb;19(2):217-21.

41.

Standard versus high-dose therapy in 10+ breast cancer.

Nieto Y, Cagnoni PJ, Jones RB.

J Clin Oncol. 1998 Feb;16(2):810-1. No abstract available.

PMID:
9469383
42.

High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes.

Bearman SI, Overmoyer BA, Bolwell BJ, Taylor CW, Shpall EJ, Cagnoni PJ, Mechling BE, Ronk B, Barón AE, Purdy MH, Ross M, Jones RB.

Bone Marrow Transplant. 1997 Dec;20(11):931-7.

43.

High-dose chemotherapy for the treatment of breast and ovarian cancer.

Cagnoni PJ, Shpall EJ.

Curr Opin Oncol. 1997 Mar;9(2):122-5. Review.

PMID:
9161788
44.

Peripheral blood stem cell harvesting and CD34-positive cell selection.

Shpall EJ, Cagnoni PJ, Bearman SI, Ross M, Nieto Y, Jones RB.

Cancer Treat Res. 1997;77:143-57. Review. No abstract available.

PMID:
9071502
45.

Peripheral blood stem cells for autografting.

Shpall EJ, Cagnoni PJ, Bearman SI, Ross M, Jones RB.

Annu Rev Med. 1997;48:241-51. Review.

PMID:
9046959
46.

Paclitaxel-containing high-dose chemotherapy: the University of Colorado experience.

Cagnoni PJ, Shpall EJ, Bearman SI, Matthes S, Ross M, Taffs S, Jones RB.

Semin Oncol. 1996 Dec;23(6 Suppl 15):43-8.

PMID:
8996598
47.

High-dose chemotherapy with AHPCS for the treatment of breast cancer. The University of Colorado results.

Cagnoni PJ, Shpall EJ, Bearman SI, Ross M, Jones RB.

Bone Marrow Transplant. 1996 Sep;18 Suppl 1:S26-9. Review.

PMID:
8899166
48.

Use of amifostine in bone marrow purging.

Cagnoni PJ, Jones RB, Bearman SI, Ross M, Hami L, Franklin WA, Capizzi R, Schein PS, Shpall EJ.

Semin Oncol. 1996 Aug;23(4 Suppl 8):44-8.

PMID:
8783666
49.

High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial.

Stemmer SM, Cagnoni PJ, Shpall EJ, Bearman SI, Matthes S, Dufton C, Day T, Taffs S, Hami L, Martinez C, Purdy MH, Arron J, Jones RB.

J Clin Oncol. 1996 May;14(5):1463-72.

PMID:
8622060
50.

Bone marrow metastases.

Shpall EJ, Gee AP, Hogan C, Cagnoni P, Gehling U, Hami L, Franklin W, Bearman SI, Ross M, Jones RB.

Hematol Oncol Clin North Am. 1996 Apr;10(2):321-43. Review.

PMID:
8707758

Supplemental Content

Loading ...
Support Center